Global Peptide Antibiotics Market Size study, by Product Type (Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomal Synthesized Peptide Antibiotics), By Disease (Skin Infection, HABP/VABP, Blood Stream Infection, Others), By Route of Administration (O

Global Peptide Antibiotics Market Size study, by Product Type (Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomal Synthesized Peptide Antibiotics), By Disease (Skin Infection, HABP/VABP, Blood Stream Infection, Others), By Route of Administration (Oral, Injectable, Topical, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecasts 2022-2028

Global Peptide Antibiotics Market is valued approximately USD 4.37 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 4.6% over the forecast period 2022-2028. The factors driving market expansion include rising demand for peptide antibiotics in hospitals and clinics, as well as an increase in the occurrence of illnesses such as bacterial skin infections, bloodstream infections, and hospital acquired infections. Furthermore, growing product approvals and product launches are likely to drive growth during the projection period. The market for peptide antibiotics is predicted to expand due to the increased frequency of central line-associated blood stream infections. According to the Australian Institute of Health and Welfare, During 2019-2020, 700 Australian public hospitals reported 1,428 instances of Staphylococcus aureus blood stream infections,. Rising demand for peptide antibiotics in hospitals and clinics, as well as an increase in the prevalence of ailments such as bacterial skin infections, bloodstream infections, and hospital acquired infections, are driving market expansion. Furthermore, rising product approvals and launches are expected to boost growth during the forecast period. Because of the increased prevalence of central line-associated blood stream infections, the market for peptide antibiotics is expected to grow. According to the Australian Institute of Health and Welfare, 700 Australian public hospitals reported 1,428 cases of Staphylococcus aureus blood stream infections in 2019-2020. Furthermore, the CDC is sponsoring programmes that help over 50 state health departments and several municipal health departments through the CDC's Antimicrobial Resistance Initiative. The CDC has also worked with state and local health departments, federal agencies, and the commercial sector to reduce the threat of antibiotic resistance. The high cost of Peptide Antibiotics, on the other hand, stifles market growth from 2022 to 2028.

The key regions considered for the Global Peptide Antibiotics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America led the peptide antibiotics market, followed by Europe. Some of the significant reasons driving development include the existence of a large number of market participants and strategic efforts implemented by prominent players. Furthermore, increased antibiotic demand in this area, as well as a rise in R&D activities in the region, are likely to boost the market throughout the projection period. Due to reasons like as increased frequency of different infectious illnesses, expanding elderly population, and increased patient knowledge about their health, Asia Pacific is predicted to be the fastest growing region throughout the forecast period.

Major market player included in this report are:
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
GSK Group of Companies
Sandoz International GmbH
Xellia Pharmaceuticals
AuroMedics Pharma LLC
Theravance Biopharma
Teva Pharmaceutical Industries Ltd
Sanofi
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Product Type
Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomal Synthesized Peptide Antibiotics
By Disease;
Skin Infection
HABP/VABP
Blood Stream Infection
Others
By Route Of Administration
Oral
Injectable
Topical
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Peptide Antibiotics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
GSK Group of Companies
Sandoz International GmbH
Xellia Pharmaceuticals
AuroMedics Pharma LLC
Theravance Biopharma
Teva Pharmaceutical Industries Ltd
Sanofi

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.